Background {#Sec1}
==========

Soft tissue sarcomas (STSs) account for less than 1 % of all cancers \[[@CR1]\]. Primary treatments for STS include surgical resection with or without adjuvant radiation; however, the 5-year probability of local recurrence and metastasis remains high \[[@CR2]--[@CR4]\].

The prognosis of STS depends on clinical and histologic characteristics. Established prognostic and predictive factors are age at diagnosis, tumor size, tumor site, histologic grade, histologic subtype, tumor depth and margin status \[[@CR5]\].

Several molecular biomarkers have also been associated with outcome in STS. For example, methylated RASSF1A was significantly related with the risk of death for STS patients \[[@CR6]\]; high serum osteopontin is correlated with poor prognosis in STS \[[@CR7]\]; Brownhill et al. have advocated use of the proliferation index (by detecting Ki-67) in a risk model of outcome for Ewing's sarcoma \[[@CR8]\]. However, this method is still under investigation and its clinical applications are limited by high costs.

The neoplasm microenvironment, as measured by a variety of blood parameters, significantly contributes to the development and progression of malignancies. For example, C-reactive protein, a non-specific blood biomarker of acute-phase inflammatory response, is often elevated in different cancer types \[[@CR9]--[@CR13]\]. Raised platelet counts predicts inferior survival in ovarian cancer, lung cancer, colon cancer, pancreatic cancer, and is potentially associated with mechanisms (such as increased thrombogenicity) that affect angiogenesis \[[@CR14]--[@CR17]\]. Additionally, patients with high neutrophil density reportedly have worse outcomes compared with those with low neutrophil density \[[@CR18]\], whereas patients with high lymphocyte density apparently have better outcomes than those with low levels \[[@CR19]\]. As NLR and PLR can be regarded as two representative indexes of systemic inflammation, we have used them to predict clinical outcome in patients with STSs.

To date, PLR has been identified as a reliable and easily accessible prognostic factor in ovarian cancer \[[@CR20]\], colorectal cancer \[[@CR21]\], breast cancer \[[@CR22]\] and non-small-cell lung cancer \[[@CR23]\]. NLR has also been shown to have prognostic value in various cancers \[[@CR24], [@CR25]\]. A meta-analysis of the prognostic value of blood NLR on clinical outcome in solid tumors showed that high NLR was associated with shorter survival \[[@CR26]\]. Nevertheless, insufficient data exists for PLR versus NLR in STS. The aim of our study was to evaluate the effects of preoperative PLR and NLR on OS, and DFS in patients with soft-tissue sarcoma.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

We included 222 STS patients who underwent extensive and radical resection at the Sun Yat-sen University Cancer Center in Guangzhou, China, between 2000 and 2010 in this retrospective study. Written informed consent was obtained from each patient. Ethical approval was given by the medical ethics committee of Sun Yat-sen University Cancer Center IRB (reference number: B2014-03-20). All patients had confirmed STS, and none had received chemotherapy before collection of the blood count data. Patients were excluded if they presented with active infections, hematological disorders or malignancies, or autoimmune disorders, or if they were on steroids. Preoperative blood cell counts were obtained within 7 days before surgery by Sysmex XE-5000™ Automated Hematology System (Shanghai, China). Data, including clinical and histopathological parameters, were collected through database chart review. Disease staging was classified according to the American Joint Committee on Cancer (AJCC)7th Edition \[[@CR27]\] and tumors were graded according to the French Federation of Cancer Centers Sarcoma Group grading system \[[@CR28]\]. Adjuvant chemotherapy was administered in 39 patients (17.6 %), and adjuvant radiotherapy treatment in 65 patients (29.3 %). Doxorubicin-based combination chemotherapy regimens were mostly used in patients with postoperative chemotherapy. Patients with stage IV disease and a single resectable metastasis qualified for surgery; postoperative RT was administered to improve local control for patients with high-grade STS or positive surgical margins. Follow-up examinations were provided by the independent follow-up program department in Sun Yat-sen University at regular intervals (every 3 months in years 1--3, 6 months in years 4--5, and 12 months in years 6--15 after diagnosis).

Statistical analysis {#Sec4}
--------------------

The primary end point of the study was OS, which was defined as the time from radical surgery to the date of death. The secondary end point of the study was DFS, which was calculated from the date of curative resection to the date of the tumor recurrence or distant metastasis. The DFS was censored at the time of death or at the last follow-up if the patient had remained disease-free by that time. Optimal cutoff values for the PLR and NLR were calculated by applying receiver operating curve (ROC) analysis. PLR was calculated as the absolute platelet count measured in × 10^9^/L, divided by the absolute lymphocyte count measured in × 10^9^/L. The NLR was calculated as the absolute neutrophil count measured in × 10^9^/L, divided by the absolute lymphocyte count measured in × 10^9^/L.

Associations between clinical and histopathological parameters with OS and DFS were analyzed using Kaplan-Meier curves and compared by the log-rank test. The chi-square (*Χ*^2^) test was used to analyze the relationship between PLR or NLR and clinicopathological parameters. Univariate and multivariate Cox-regression analyses were performed to determine effects of probable prognostic factors, including age, gender, performance status, diabetes mellitus, cardiopulmonary disease, smoking history, tumor depth, tumor site, tumor size, grade, adjuvant radiotherapy, adjuvant chemotherapy and AJCC stage on OS and DFS. Hazard ratios (HRs) estimated from the Cox analysis were reported as relative risks with corresponding 95 % confidence intervals(CIs). All analyses were performed using the SPSS statistical software package (SPSS statistics 17.0). *P* \< 0.05 was considered as statistically significant.

Results {#Sec5}
=======

Patient characteristics and histologic subtype {#Sec6}
----------------------------------------------

The median age of the 222 patients with histologically confirmed STS who were included in the present study at surgery was 37 years (range, 5--78 years), and their median follow-up time was 74 months (range, 1--176 months \[censored\]). Patients were classified into different subtypes as shown in Table [1](#Tab1){ref-type="table"}.Table 1Histologic typeNumberPercentUndifferentiated pleomorphic sarcoma/MFH5926.6Fibrosarcoma209.0Dermatofibrosarcoma proberans2812.6Well-differentiated liposarcoma135.9Myxoid liposarcoma125.4Pleomorphic liposarcoma52.3Leiomyosarcoma135.9Rhabdomyosarcoma104.5Synovial sarcoma2812.6Epithelioid sarcoma10.5Angiosarcoma83.6Alveolar soft part sarcoma52.3MPNST104.5PNET62.7Malignant Triton Tumor10.5Mesenchymal chondrosarcoma31.4

Patients' mean blood values were as follows: platelet count: 252.02 ± 94.752; neutrophil count: 4.468 ± 2.543; lymphocyte count: 2.151 ± 0.707; PLR: 132.069 ± 80.600; and NLR: 2.407 ± 2.395. We used ROC analysis criteria to determine the optimal cutoffs as 133.915 (AUC: 0.640, 95 % CI: 0.541--0.739, *P* = 0.005), and 2.5 (AUC: 0.632, 95 % CI: 0.533--0.731, *P* = 0.009) for PLR and NLR, respectively.

Relationships between PLR or NLR and other clinical characteristics {#Sec7}
-------------------------------------------------------------------

Elevated PLR was significantly associated with female sex, poor performance status, diabetes mellitus, smoking history, deep tumor depth, high tumor grade and large tumor size; Elevated NLR was significantly associated with poor performance status, deep tumor depth, high tumor grade, large tumor size, deep tumor site and high AJCC stage (Table [2](#Tab2){ref-type="table"}).Table 2Clinical-pathological characteristics of soft tissue sarcoma patientOverall population *N* (%)PLRNLR\<133.915≥133.915*P*\<2.5≥2.5*PN* = 146*N* = 76*N* = 160*N* = 62Age at operation(years)0.0910.067\<65205(92.3)138(94.5)67(88.2)151(94.4)54(87.1)≥6517(7.7)8(5.5)9(11.8)9(5.6)8(12.9)Gender**0.02**0.206Female96(43.2)55(37.7)41(53.9)65(40.6)31(50.0)Male126(56.8)91(62.3)35(46.1)95(59.4)31(50.0)Performance status**0.002\<0.001**0 \~ 1173(77.9)123(84.2)50(65.8)137(85.6)35(58.1)≥249(22.1)23(15.8)26(34.2)23(14.4)26(41.9)Diabetes mellitus**0.013**0.067Yes4(1.8)0(0)4(5.3)1(0.6)3(4.8)No218(98.2)146(100.0)72(94.7)159(99.4)59(95.2)Cardiopulmonary disease1.0001.000Yes12(5.4)8(5.5)4(5.3)9(5.6)3(4.8)No210(94.6)138(94.5)72(94.7)151(94.4)59(95.2)Ever smoked**0.003**0.300Yes34(15.3)30(20.5)4(5.3)27(16.9)7(11.3)No188(84.7)116(79.5)72(94.7)133(83.1)55(88.7)Tumor depth**0.0240.001**Superficial87(39.2)65(44.5)22(28.9)74(46.3)13(21.0)Deep135(60.8)81(55.5)54(71.1)86(53.8)49(79.0)Tumor grade**0.0280.047**G165(29.3)50(34.2)15(19.7)55(34.4)10(16.1)G299(44.6)65(44.5)34(44.7)67(41.9)32(51.6)G336(16.2)17(11.6)19(25.0)23(14.4)13(21.0)Unknown22(9.9)14(9.6)8(10.5)15(9.4)7(11.3)Tumor size**0.005\<0.001**\<5 cm105(47.3)79(54.1)26(34.2)88(55.0)17(27.4)≥5 cm117(52.7)67(45.9)50(65.8)72(45.0)45(72.6)Tumor site0.282**0.002**Upper extremity21(9.5)11(7.5)10(13.2)18(11.3)3(4.8)Lower extremity60(27.0)41(28.1)19(25.0)46(28.8)14(22.6)Thoracic/trunk77(34.7)54(37.0)23(30.3)62(38.8)15(24.2)Intra-abdomina35(15.8)19(13.0)16(21.1)17(10.6)18(29.0)Head-neck29(13.1)21(14.4)8(10.5)17(10.6)12(19.4)AJCC stage0.056**0.002**IA + IB68(30.6)52(35.6)16(21.1)57(35.6)11(17.7)IIA + IIB107(48.2)68(46.6)9(51.3)77(48.1)30(48.4)III + IV34(15.3)17(11.6)17(22.4)16(10.0)18(29.0)Unknown13(5.9)9(6.2)4(5.3)10(6.3)3(4.8)Bold print indicates statistical significance

Prognostic significance of the clinical characteristics in STS {#Sec8}
--------------------------------------------------------------

In univariate analysis, we found significant associations of performance status, tumor depth, tumor grade, tumor size, tumor site, AJCC stage, PLR and NLR with OS and DFS. In multivariate analysis, we observed significant associations of tumor site, AJCC stage and PLR, but not NLR with OS (Table [3](#Tab3){ref-type="table"}). And significant associations remained among tumor depth, AJCC stage and PLR with DFS (Table [4](#Tab4){ref-type="table"}). Multivariate analyses were performed based on age at surgery, gender, performance status, diabetes mellitus, cardiopulmonary disease, smoking history, tumor depth, tumor site, AJCC stage, adjuvant radiotherapy, adjuvant chemotherapy, PLR and NLR. The reason why factors such as tumor grade and tumor size were excluded is to eliminate the influence of statistical collinearity. Another multivariate analysis model including tumor grade and tumor size is available (Additional file [1](#MOESM1){ref-type="media"}: Table S1 and Additional file [2](#MOESM2){ref-type="media"}: Table S2).Table 3Univariate and multivariate Cox proportional analysis regarding overall survivalUnivariate analysisMultivariate analysisParameterHR (95 % CI)*P*-valueHR (95 % CI)*P*-valueAge at operation(years)\<651 (referent)0.2201 (referent)0.219≥651.70(0.73-4.00)2.06(0.65-6.49)GenderFemale1 (referent)0.7721 (referent)0.615Male1.09(0.62-1.89)1.20(0.59-2.45)Performance status0 \~ 11 (referent)**0.006**1 (referent)0.975≥22.22 (1.26-3.93)0.99 (0.48-2.03)Diabetes mellitusNo1 (referent)0.9431 (referent)0.218Yes1.07(0.15-7.78)0.27(0.03-2.18)Cardiopulmonary diseaseNo1 (referent)0.3441 (referent)0.342Yes0.38(0.06-2.78)0.33(0.03-3.27)Ever smokedNo1 (referent)0.5791 (referent)0.273Yes1.23(0.60-2.52)1.69 (0.66-4.32)Tumor depthSuperficial1 (referent)**\<0.001**1 (referent)0.096Deep6.09 (2.74-13.53)2.41(0.85-6.77)Tumor gradeG11 (referent)**0.002**NANAG24.66(1.78-12.22)**\<0.001**G39.27(3.16-27.20)Tumor size\<5 cm1 (referent)**0.001**NANA≥5 cm2.87(1.55-5.32)Tumor siteTrunk&extremity1 (referent)**\<0.001**1 (referent)**0.002**head/neck&intra-abdominal4.48(2.57-7.81)3.14 (1.52-6.48)AJCC stageIA + IB1 (referent)**0.001**1 (referent)**0.002**IIA + IIB5.13(1.97-13.37)**\<0.001**3.92 (1.43-10.76)**0.008**III + IV10.56 (3.71-30.08)7.45(2.44-22.81)Adjuvant radiotherapyYes1 (referent)0.7981 (referent)0.692No1.08 (0.60-1.95)0.86(0.40-1.84)Adjuvant chemocherapyYes1 (referent)0.3201 (referent)0.929No1.44 (0.70-2.97)1.04(0.45-2.41)PLR\<133.915z1 (referent)**0.002**1 (referent)**0.019**≥133.9152.49 (1.41-4.39)2.60(1.17-5.74)NLR\<2.51 (referent)**\<0.001**1 (referent)0.881≥2.52.83 (1.61-4.99)1.06(0.52-2.16)Bold print indicates statistical significanceTable 4Univariate and multivariate Cox proportional analysis regarding disease-free-survivalUnivariate analysisMultivariate analysisParameterHR (95 % CI)*P*-valueHR (95 % CI)*P*-valueAge at operation(years)\<651 (referent)0.3621 (referent)0.370≥651.47 (0.64-3.37)1.69(0.54-5.31)GenderFemale1 (referent)0.4361 (referent)0.643Male0.85(0.56-1.29)0.89(0.54-1.46)Performance status0 \~ 11 (referent)**0.001**1 (referent)0.596≥21.81(1.15-2.85)1.16(0.68-1.97)Diabetes mellitusNo1 (referent)**0.02**1 (referent)0.575Yes5.51(1.31-23.09)0.66(0.16-2.78)Cardiopulmonary diseaseNo1 (referent)0.5101 (referent)0.247Yes0.68(0.21-2.15)2.52(0.53-12.06)Ever smokedNo1 (referent)0.4701 (referent)0.064Yes1.23 (0.70-2.19)1.95(0.96-3.96)Tumor depthSuperficial1 (referent)**\<0.001**1 (referent)**0.002**Deep4.07 (2.39-6.93)2.841.47-5.49)Tumor gradeG11 (referent)**0.003**NANAG22.54 (1.37-4.71)**\<0.001**G36.71(3.43-13.12)Tumor size\<5 cm1 (referent)**\<0.001**NANA≥5 cm2.22(1.43-3.45)Tumor siteTrunk&extremity1 (referent)**\<0.001**1 (referent)0.132head/neck&intra-abdominal2.26 (1.48-3.46)1.49(0.89-2.52)AJCC stageIA + IB1 (referent)**0.001**1 (referent)**0.002**IIA + IIB2.72(1.51-4.89)**\<0.001**1.85(0.98-3.50)0.057III + IV5.37(2.72-10.61)3.60(1.74-7.46)Adjuvant radiotherapyYes1 (referent)0.2161 (referent)0.560No1.31(0.85-2.03)1.17(0.70-1.95)Adjuvant chemocherapyYes1 (referent)0.3161 (referent)0.753No1.30(0.78-2.19)1.10(0.61-1.97)PLR\<133.9151 (referent)**0.011**1 (referent)**0.032**≥133.9151.75(1.14-2.70)1.77(1.05-2.97)NLR\<2.51 (referent)**0.018**1 (referent)0.516≥2.51.71(1.10-2.66)0.83(0.48-1.44)Bold print indicates statistical significance

Prognostic significance of PLR and NLR in STS {#Sec9}
---------------------------------------------

In univariate analysis, shorter OS was significantly associated with both high PLR (HR: 2.49; 95 % CI: 1.41--4.39; *P* = 0.002; Table [3](#Tab3){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}) and high NLR (HR: 2.83; 95 % CI: 1.61--4.99; *P* \< 0.001; Table [3](#Tab3){ref-type="table"}). In multivariate analysis, tumor site, AJCC stage, and PLR (HR: 2.60; 95 % CI: 1.17--5.74, *P* = 0.019) were still identified as independent prognostic factors (Table [3](#Tab3){ref-type="table"}; Additional file [3](#MOESM3){ref-type="media"}: Table S3), but NLR was not (Table [3](#Tab3){ref-type="table"}; Additional file [4](#MOESM4){ref-type="media"}: Table S4). Patients with high PLR had a median OS of 62 months, whereas those with low PLR had a median OS of 76 months. In univariate analyses, shorter DFS was associated with both high PLR (HR: 1.75; 95 % CI: 1.14--2.70, *P* = 0.011; Table [4](#Tab4){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}) and high NLR (HR: 1.71; 95 % CI: 1.10--2.66, *P* = 0.018; Table [4](#Tab4){ref-type="table"}). However, elevated PLR (HR: 1.77; 95 % CI: 1.05--2.97, *P* = 0.032) but not NLR was independently associated with decreased DFS in multivariate analysis (Table [4](#Tab4){ref-type="table"}). Patients with high PLR had a median DFS of 18 months, and those with low PLR had a median DFS of 57 months.Fig. 1Kaplan-Meier curves for overall survival of patients with soft tissue sarcoma by low vs high platelet-lymphocyte ratio. PLR **≥** 133.915 is associated with poor survival (*P* = 0.001)Fig. 2Kaplan-Meier curves for disease-free survival of patients with soft tissue sarcoma by low vs high platelet-lymphocyte ratio. PLR **≥** 133.915 is associated with poor survival (*P* = 0.01)

Prognostic significance of PLR in different histologic types of STS {#Sec10}
-------------------------------------------------------------------

In subgroup analyses of the four major histologic types (undifferentiated \[spindle cell and pleomorphic\] sarcoma, fibrosarcoma, liposarcoma, and leiomyosarcoma), high PLR was associated with shorter OS in undifferentiated sarcoma in univariate analysis (HR: 3.50; 95 % CI: 1.21--10.11; *P* = 0.021; Table [5](#Tab5){ref-type="table"}) and remained significant in multivariate analysis (HR: 3.91; 95 % CI: 1.02--14.99; *P* = 0.047; Table [5](#Tab5){ref-type="table"}).Table 5Association of prognostic factors and PLR with overall survival in specific histologic tumor typesUnivariate analysisMultivariate analysisParameterHR (95 % CI)*P*-valueHR (95 % CI)*P*-valueUndifferentiated(spindle cell and pleomorphic) sarcoma1 (referent)**0.021**1 (referent)**0.047**3.50(1.21-10.11)3.91(1.02-14.99)Fibrosarcoma1 (referent)0.1601 (referent)0.1572.81(0.67-11.81)3.16(0.64-15.59)Liposarcoma1 (referent)0.1771 (referent)NA5.22(0.47-57.67)NALeiomyosarcoma1 (referent)0.4251 (referent)NA2.08(0.34-12.62)NABold print indicates statistical significance

Discussion {#Sec11}
==========

Our present study showed that high preoperative PLR is independently associated with survival in patients who underwent extensive radical surgery.

Accumulating evidence has shown that platelets can support various steps of cancer development and tumor progression by promoting cancer cell proliferation, tumor angiogenesis and metastasis. In addition to their function in hemostasis, platelets are also involved in inflammatory disease and cancer \[[@CR29]\]. Platelets reportedly have a stimulatory effect on ovarian cancer cell proliferation via the transforming growth factor (TGF)-β \[[@CR30]\]. They have also been shown in vitro to inhibit apoptosis and reverse cell-cycle arrest induced by chemotherapeutic agents (such as 5-fluorouracil and paclitaxel) and enhance DNA repair in cancer cells \[[@CR31]\]. Secondly, as tumor growth seems to depend on the formation of new blood vessels \[[@CR32]\], platelets, which carry a variety of proangiogenic factors, affect regulation of cancer angiogenesis. Interestingly, cancer cells were also suggested to induce release of vascular endothelial growth factor from platelets, resulting in angiogenesis \[[@CR33]\]. Platelets have been linked to tumor metastasis \[[@CR34], [@CR35]\] with underlying mechanisms that include attenuating the ability of natural killer cells to shield circulating cancer cells against the immune system \[[@CR36]\] and inducing epithelial--mesenchymal transition \[[@CR37]\].

As with platelets, lymphocytes are a significant blood parameter related to immune surveillance. Thus, high lymphocytic infiltrate is associated with improved survival and superior response to systemic therapy \[[@CR38], [@CR39]\] whereas a low peripheral blood lymphocyte counts are related to poor cancer prognoses \[[@CR40], [@CR41]\].

A combined index of platelet and lymphocyte counts has been investigated as prognostic factor for some cancers. Recently, a meta-analysis, comprising 12,754 patients, of the association of blood PLR and overall survival in solid tumors concluded that high PLR was independently associated with shorter OS in various solid tumors \[[@CR42]\]. Asher et al. reported that high preoperative PLR was associated with poor survival in ovarian cancer \[[@CR20]\]; and Krenn-Pilko et al. found that preoperative PLR as an independent prognostic marker for survival in breast cancer patients \[[@CR22]\]. Szkandera et al. evaluated the prognostic significance of PLR in STS patients and found statistically significant associations in univariate, but not multivariate analyses, and that high preoperative NLR was an independent prognostic factor in multivariate analysis \[[@CR43], [@CR44]\], which differed from our results. However, their studies used different cancer populations, different NLR and PLR cut-off values, and patient cohorts of a different median age from our study, which might hinder the comparability of their results with ours. Moreover, these inflammatory factors may be affected by potential confounding factors, including smoking history, performance status and co-morbidities. Thus, the significance of inflammatory markers in STS requires further evaluation.

Findings that PLR is superior to NLR in predicting clinical outcomes vary in different studies that address different cancers. Our findings are consistent with some prior studies \[[@CR20], [@CR45]\], but not others \[[@CR46], [@CR47]\]. As we have mentioned, differences in race \[[@CR48]\] or cutoff values may affect the results. Racial variations are known to affect cutoff values. For example, Caucasians have higher peripheral blood neutrophil counts and lower lymphocyte counts than do Asians \[[@CR49]\]; NLR ≥ 5 was considered high in reports on Caucasian patients \[[@CR50]--[@CR52]\], whereas some studies on Asian patients used NLR \>3 and \>4 as cutoff points \[[@CR53], [@CR54]\]. For PLR, some reports used 150 or 300 as cutoff points \[[@CR21], [@CR53]\], some studies identified the ideal cutoff value by applying ROC curve and the cutoff points \[[@CR22], [@CR23]\].

Our findings provide a new and valuable clue for diagnosing and monitoring STS. Prediction of disease progression is not only determined by the use of clinical or histopathological factors including tumor grade, tumor size, and tumor site but also by host-response factors \[[@CR55]\], such as performance status, weight loss, and systemic inflammatory response \[[@CR56]\]. They also significantly affect clinical outcomes \[[@CR57]\]. Thus, PLR can be used to enhance clinical prognostication. Furthermore, the PLR can be assessed from peripheral blood tests that are routinely available without any other complicated expenditure, thus providing lower cost and greater convenience for the prognostication.

Nevertheless, this study has some limitations, namely its retrospective research design. The unavailability of data regarding cancer-specific survival is another limitation. Choi et al. assessed multiple preoperative systemic inflammatory serum markers and predicted an association between high inflammatory status and shorter disease-specific survival in STS \[[@CR58]\]. They showed that inflammatory marker values were significantly associated with histologic grade. Furthermore, the presence of multiple elevated markers was the most significant predictor of disease-specific survival. As NLR may vary by race \[[@CR59]\], the fact that \> 95 % of our patients were Asians is another limitation. Additionally, thrombocytosis and lymphocytopenia could have other causes, including bacterial infections, connective tissue disorders, intense physical exercise, severe stress. Nevertheless, the association of poor clinical outcome with high PLR in our results has not been challenged, considering these limitations.

Conclusion {#Sec12}
==========

Our study indicates that PLR is an independent prognostic factor for survival of STS. Validation studies or large-scale prospective studies are warranted to verify our findings.
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